JAMDA
Volume 8, Issue 4 , Pages 209-218, May 2007

Constipation in Long-Term Care

  • Syed H. Tariq, MD, FACP

      Affiliations

    • Corresponding Author InformationAddress correspondence to Syed H. Tariq, MD, FACP, 1402 South Grand Boulevard, M-238, Division of Geriatric Medicine, Saint Louis University, St Louis, MO 63104.

Division of Geriatric Medicine, Saint Louis University, St Louis, MO

Constipation is more common in older adults and accounts for increased physician office visits and hospital admissions. There is lack of agreement on the definition of constipation regarding what patients perceive as constipation and what physicians traditionally see as constipation. Constipation is related to multiple factors, and when left untreated or not properly treated, results in complications, such as impaction, even perforation and death. Laxative use increases with age and at times multiple agents are used to relieve symptoms of constipation. Currently the most commonly used laxative is stool softener but it lacks efficacy. From the review of literature, osmotic laxatives are effective in older adults and well tolerated. Psyllium, a bulk laxative, is also effective in the treatment of constipation, while there is limited evidence for stimulants, dioctyl sulfosuccinate, and other bulk laxatives such as calcium polycarbophil and methylcellulose. A new drug, lubiprostone, is a type 2-chloride channel activator and is shown to be effective, safe, and well tolerated in older adults treated for chronic constipation in studies up to a year. It appears to be particularly useful in persons who have recurrent fecal impaction and in those with severe chronic constipation. There is a need for a large-scale trial examining an appropriate cost-effective approach to the management of constipation in the nursing home.

Keywords: Constipation, longterm, older adults, causes and treatment options

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Conflict of Interest: S.H.T. has attended one advisory board meeting for Sucampo Pharmaceuticals.

PII: S1525-8610(07)00173-9

doi:10.1016/j.jamda.2007.02.009

JAMDA
Volume 8, Issue 4 , Pages 209-218, May 2007